- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.12.24 | Novartis gains rights to PTC's Huntington's programme in deal worth up to $2.9bn | ||
| 03.12.24 | Amgen's investigational weight-loss drug MariTide shows promise in mid-stage study | ||
| 03.12.24 | Bridging gaps and breaking barriers in pharma alliances | ||
| 02.12.24 | MHRA urges companies to prepare for Windsor Framework for medicines | ||
| 02.12.24 | Merck shares positive phase 3 results for pulmonary arterial hypertension therapy | ||
| 02.12.24 | Enabling a sustainable and mutually beneficial CDMO partnership | ||
| 29.11.24 | UK researchers uncover first new asthma and COPD attack treatment in 50 years | ||
| 29.11.24 | GSK granted EC approval for meningococcal disease vaccine Menveo | ||
| 29.11.24 | Galderma announces positive late-stage results for nemolizumab in prurigo nodularis | ||
| 29.11.24 | Health equity: what will you do? | ||
| 28.11.24 | AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study | ||
| 28.11.24 | BeiGene's Tevimbra approved by EC for first-line gastric and oesophageal cancer use | ||
| 28.11.24 | Sanofi opens €558m modular concept manufacturing facility in Singapore | ||
| 28.11.24 | How the 'five Ps' can close health equity gaps | ||
| 27.11.24 | Novartis' Kisqali granted EC approval to treat early breast cancer patients | ||
| 27.11.24 | GSK's linerixibat shows promise in phase 3 primary biliary cholangitis trial | ||
| 27.11.24 | FDA approves Shorla Oncology's Imkeldi to treat leukaemia and other cancers | ||
| 27.11.24 | All hands on deck | ||
| 26.11.24 | Roche expands cell therapy capabilities with $1.5bn Poseida acquisition | ||
| 26.11.24 | AstraZeneca announces $3.5bn US investment to boost research and manufacturing | ||
| 26.11.24 | Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis | ||
| 26.11.24 | Langland appoints Gemma Cathcart as managing partner | ||
| 26.11.24 | Why the patient voice is the secret to re-energising the healthcare sector | ||
| 25.11.24 | Novartis and Ratio enter radiotherapeutics partnership worth $745m | ||
| 25.11.24 | J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
